Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BYLaryngoscope investigative otolaryngology

Treatment of Frey's Syndrome With "Ready to Use Liquid" Relabotulinumtoxin A (Relfydess).

  • Loris Zoller1,2
  • Philipp Reddiess1,2
  • Justus Müller-Goebel1,2
  • Tobias Kleinjung1,2
  • Daniel Runggaldier1,2,3
  1. 1Department of Otorhinolaryngology, Head and Neck Surgery University Hospital Zurich Zurich Switzerland.
  2. 2University of Zurich Zurich Switzerland.
  3. 3Division of Phoniatrics and Speech Pathology, Department of Otorhinolaryngology, Head and Neck Surgery University Hospital Zurich Zurich Switzerland.
Read full textPDFDOICite

Abstract

Objective

To describe the off-label intradermal use of ready-to-use liquid relabotulinumtoxinA (Relfydess) for symptomatic Frey's syndrome after parotidectomy.Methods

A 72-year-old man with gustatory sweating and flushing after total parotidectomy and adjuvant radiotherapy, who had previously responded to conventional botulinum toxin A, underwent gustatory provocation, clinical mapping, and intradermal relabotulinumtoxinA injections using a 1-cm² grid. Clinical response and treatment-related adverse events were assessed at 6 weeks and 3 months.Results

At 6 weeks and 3 months, the patient reported symptom reduction comparable to his previous treatment with conventional botulinum toxin A. At 3 months, repeat gustatory stimulation elicited no visible sweating. No treatment-related adverse events were observed.Conclusion

In this patient, ready-to-use liquid relabotulinumtoxinA provided sustained symptom control for 3 months without observed adverse events. This formulation may offer a practical off-label option for previously responsive patients, while product-specific potency units should not be considered interchangeable.Level of evidence

5.

Related

  1. Potential role of resveratrol in abdominal cocoon syndrome: targeting inflammation, oxidative stress, and fibrosis via food-derived bioactive compounds resveratrol for treatment of abdominal cocoon syndrome
    Hailong Guo, Minglei Bi
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  2. Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
    Yueqi Wang, Siqi Wang, Huijuan Fan +6
    ImmunotherapyPeer-reviewedLicence not statedFull textNeurologyPMC
  3. Ketamine Infusion Protocol for the Treatment of Complex Regional Pain Syndrome
    Evan B Hershman, Tony L Wang
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Polyendocrine metabolic ovarian syndrome: a new name to support better treatment.
    Ginevra Mills
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadiennePeer-reviewedCC BY-NC-NDFull textObstetrics, gynaecology & paediatricsEurope PMC
  5. HDAC inhibitor treatment restores transcriptome, chromatin accessibility, and memory deficits in a mouse model for Down syndrome
    Cesar Sierra, René A.J. Crans, Mara Dierssen
    ISciencePeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{zoller2026treatment,
  title = {{Treatment of Frey's Syndrome With "Ready to Use Liquid" Relabotulinumtoxin A (Relfydess).}},
  author = {Loris Zoller and Philipp Reddiess and Justus Müller-Goebel and Tobias Kleinjung and Daniel Runggaldier},
  journal = {Laryngoscope investigative otolaryngology},
  year = {2026},
  month = oct,
  doi = {10.1002/lio2.70618},
  url = {https://europepmc.org/article/MED/42908782},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Treatment of Frey's Syndrome With "Ready to Use Liquid" Relabotulinumtoxin A (Relfydess).
AU  - Loris Zoller
AU  - Philipp Reddiess
AU  - Justus Müller-Goebel
AU  - Tobias Kleinjung
AU  - Daniel Runggaldier
PY  - 2026
DA  - 2026/10/20
JO  - Laryngoscope investigative otolaryngology
DO  - 10.1002/lio2.70618
UR  - https://europepmc.org/article/MED/42908782
AB  - Objective  To describe the off-label intradermal use of ready-to-use liquid relabotulinumtoxinA (Relfydess) for symptomatic Frey's syndrome after parotidectomy.Methods  A 72-year-old man with gustatory sweating and flushing after total parotidectomy and adjuvant radiotherapy, who had previously responded to conventional botulinum toxin A, underwent gustatory provocation, clinical mapping, and intradermal relabotulinumtoxinA injections using a 1-cm² grid. Clinical response and treatment-related adverse events were assessed at 6 weeks and 3 months.Results  At 6 weeks and 3 months, the patient reported symptom reduction comparable to his previous treatment with conventional botulinum toxin A. At 3 months, repeat gustatory stimulation elicited no visible sweating. No treatment-related adverse events were observed.Conclusion  In this patient, ready-to-use liquid relabotulinumtoxinA provided sustained symptom control for 3 months without observed adverse events. This formulation may offer a practical off-label option for previously responsive patients, while product-specific potency units should not be considered interchangeable.Level of evidence  5.
SN  - 2378-8038
ER  -